Selective Innovation To Dictate The Parameters Of Substantiation For The Market

Posted by Merin John on June 30th, 2021

The healthcare vertical, which has always been one of the evolving ecosystems, is amongst the most happening things as of now and the situation is bound to continue in the forecast period as well. One of those evolutions is “patient-centricity”. In other words, it would be the patients calling the shots now. This trend has been entailed by the Ineffective Esophageal Motility Treatment Market.

Ineffective esophageal motility treatment leads to a reduction in muscle damage and improved outcomes, improving quality of life and resulting in long-term benefits. Device-based treatment and IEMT drugs have already had a substantial impact on how symptoms of GERD and achalasia are treated. The first and the most important factor driving the growth of the ineffective esophageal motility treatment market is the increasing prevalence of gastroesophageal reflux disease. Other factors, such as intake of asthma medications and increasing geriatric population, are also responsible for driving the ineffective esophageal motility treatment market.

According to the latest report published by PMR, the global ineffective esophageal motility treatment market is projected to expand at a decent CAGR of around 6% during the forecast period (20202030).

Get Sample Copy of this Report @

Company Profiles:

  •          Johnson & Johnson
  •          Mylan Pharmaceutical
  •          MediGus Ltd.
  •          Torax Medical
  •          Medtronic plc.
  •          AstraZeneca plc.
  •          Teva Pharmaceutical Industries Ltd.
  •          Takeda Pharmaceutical Company Limited
  •          GlaxoSmithKline plc.
  •          Bayer AG
  •          Pfizer Inc.
  •          Bausch Health Companies Inc.
  •          LABORIE
  •          Mederi Therapeutics, Inc.
  •          Becton, Dickinson and Company (C. R. Bard, Inc.)
  •          EndoGastric Solutions, Inc
  •          Olympus
  •          Pentax

Key Takeaways from Ineffective Esophageal Motility Treatment Market Study

  •          Significant advantages of ineffective esophageal motility treatment; improving reimbursement scenario for surgical treatment devices; increasing awareness regarding gastric reflux disease; and large patient pool for GERD, dysphagia, achalasia, and burning chest pain are key factors propelling the growth of ineffective esophageal motility treatment market in developing regions.
  •          North America is a prominent region the global ineffective esophageal motility treatment market, while East Asia is expected to offer lucrative growth opportunities, owing to the large population base and higher incidence of GERD and dysphagia.
  •          Higher OTC antacid consumption is poised to drive the growth of the market.
  •          Radiofrequency ablation systems with high level precision and procedural advantages over myotomy are expected to generate significant revenue in the long term.
  •          Increasing adoption of ineffective esophageal motility treatment drugs for quick recovery as compared to device-based treatment marks higher revenue potential.
  •          Raw material procurement issues, drug shortages, and reduced patient visits amidst the COVID-19 pandemic will adversely affect the growth of the ineffective esophageal motility treatment market in the near term.

“Procedural accuracy achieved by treatment devices and affordability of drug-based treatment are anticipated to drive the ineffective esophageal motility treatment market. Additionally, the large patient pool will bring in steady revenue opportunities,” says a PMR analyst.

New Product Launches by Key Players to Strengthen Market Presence

Key manufacturers in the ineffective esophageal motility treatment market are mainly focusing on research & development and introduction new & advanced treatment products. For example, LINX is the new and advanced version of the LINX reflux management device that is used for the transoral incision-less fundoplication process, which is one of the important procedures for the treatment of gastroesophageal reflux disease. The innovation of new & advanced products is a factor boosting the ineffective esophageal motility treatment market. In addition, Olympus Corporation has launched advanced versions of esophagoscopes, which have improved the treatment curve of gastroesophageal reflux disease. Manufacturers are focusing on extended indication list and higher reimbursement to draw demand and increase profitability. Alternatively, a key factor affecting the ineffective esophageal motility treatment market is the entry of generic drug manufacturers. Market leaders are constantly working on strengthening their strategies to gain market share.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the ineffective esophageal motility treatment market in its latest study, presenting historical demand assessment of 20152019 and projections for 20202030, on the basis of product (drugs and devices), indication (GERD, dysphagia, achalasia, and burning chest pain), and end user (institutional sales and retail sales), across seven key regions.

Like it? Share it!

Merin John

About the Author

Merin John
Joined: December 11th, 2020
Articles Posted: 262

More by this author